MED
Medifast, Inc.12.03
+0.03+0.25%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
132.23MP/E (TTM)
601.50Basic EPS (TTM)
0.02Dividend Yield
0%Recent Filings
8-K
Medifast Q3 revenue plunges 36%
Medifast reported Q3 2025 revenue of $89.4 million, down 36.2% from $140.2 million last year, as active earning OPTAVIA coaches fell 35% to 19,500 amid GLP-1 medication pressures. The company swung to a $2.3 million net loss from prior profit, yet holds $173.5 million in cash with no debt. Revenue per coach dipped slightly to $4,585. It eyes Q4 revenue of $65-80 million, betting on metabolic health pivot.
10-Q
Q3 FY2025 results
Medifast's Q3 revenue fell 36.2% year-over-year to $89.4 million, driven by a 35% drop in active earning OPTAVIA coaches to 19,500 amid client acquisition challenges from GLP-1 medication adoption, while gross margin slipped to 69.5% from 75.4% due to fixed cost leverage loss and a $1.6 million Essential product reformulation reserve. Operating loss widened to $4.1 million from $2.1 million profit, with SG&A down 36% but still pressuring margins; net loss hit $2.3 million or $(0.21) diluted EPS, anti-dilutive amid the loss position. Cash flow from operations generated $12.1 million year-to-date, bolstering cash and equivalents to $99.5 million with no debt after terminating the $225 million revolver in October 2024. Free cash flow stood at $7.9 million year-to-date (derived). Coaches fuel growth. Yet competition from pharmaceuticals looms large.
8-K
Medifast Q2 revenue plunges 37%
Medifast reported Q2 2025 revenue of $105.6 million, down 37.4% from $168.6 million last year, as active earning OPTAVIA coaches fell 32.7% to 22,800 amid client acquisition hurdles and GLP-1 drug competition. Net income swung to $2.5 million, or $0.22 per share, boosted by a $2.0 million after-tax gain from selling its LifeMD stake, while operations lost $1.1 million—better than prior year's $7.9 million shortfall. Cash remains robust at $162.7 million with no debt. Q3 guidance projects $70-90 million revenue and ($0.60) to $0.00 EPS. Coach growth stalls.
10-Q
Q2 FY2025 results
Medifast's revenue fell 37.4% year-over-year to $105.6 million in Q2 FY2025 ended June 30, 2025, driven by fewer active earning OPTAVIA coaches at 22,800, down 32.7% from last year, while gross margin slipped 0.6 points to 72.6% on lower volumes. Operating loss narrowed to $1.1 million from $7.9 million, thanks to sharp SG&A cuts including non-recurring supply chain costs from 2024, but net income swung to $2.5 million or $0.22 diluted EPS—reconciled against 11.1 million shares—from a $8.2 million loss, boosted by a $2.6 million gain on selling the LifeMD stake. Cash equivalents rose to $101.7 million with $28 thousand operating cash flow and $11.3 million free cash flow (derived), no debt after terminating the credit facility. Sold LifeMD investment in Q2 for $3.3 million realized gain (six-month), collaboration ongoing. GLP-1 medications intensify competition, eroding client acquisition.
8-K
Medifast approves plan amendment
Medifast stockholders re-elected all seven board directors and approved key proposals at the June 18, 2025 annual meeting, including ratification of RSM US LLP as auditors and advisory endorsement of executive pay. Crucially, they greenlit an amendment to the 2012 Share Incentive Plan, boosting available shares by 550,000 to roughly 1,175,000 for attracting talent. This bolsters equity incentives amid performance pressures. Plan lasts until 2035.
IPO
Website
Employees
Sector
Industry
HLF
Herbalife Ltd.
14.45-0.45
IMTH
Innovative MedTech Inc.
0.08+0.00
LFMD
LifeMD, Inc.
3.42+0.15
MDT
Medtronic plc.
97.72-0.85
MRM
MEDIROM Healthcare Technologies
2.10+0.01
MWAI
MedwellAI, Inc.
0.52+0.00
OPCH
Option Care Health, Inc.
32.93-0.61
SG
Sweetgreen, Inc.
6.91-0.34
WOOF
Petco Health and Wellness Compa
3.05-0.05
WW
WW International, Inc.
27.23+2.94